The denial of patent to Glivec was the first case of a multinational being denied patent protection for a drug that enjoys monopoly marketing rights in about 40 countries.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
Novartis's famed cancer drug, Glivec, will not get patent protection in India. The apex body on patent and trademark disputes, the Intellectual Property Appellate Board (IPAB), has ruled that the drug "lacks innovation" and the high price tag of Rs 120,000 per month per patient would be too high for the common man.
Perfetti has won the suit against Candico that was filed 9 years ago over the latter's trademark.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances